leadf
logo-loader
viewAnteris Technologies Ltd

Anteris Technologies’ 3D single-piece aortic valve DurAVR™ a ‘Best Innovation’ at PCR London Valves 2020

Data from its first-in-human trial will be presented at the conference to be held on November 22-24, 2020, virtually, given the COVID-19 restrictions.

Anteris Technologies Ltd - Anteris Technologies’ 3D single-piece aortic valve DurAVR™ picked ‘Best Innovation’ at PCR London Valves 2020
The Anteris DurAVR™ is the only aortic valve being featured in the Best Innovations section

Anteris Technologies Ltd’s (ASX:AVR) (OTCMKTS:AMEUF) (FRA:DDF) 3D single-piece aortic valve DurAVR™ has been selected as a 'Best Innovation' at the PCR London Valves 2020 virtual conference.

Data from the company’s first-in-human trial will be presented at the conference to be held on November 22-24, 2020, virtually, given the COVID-19 restrictions. 

Superior performance and durability

Anteris chief executive officer Wayne Paterson said: “To be featured as a Best Innovation at PCR London Valves is a highly coveted honour, with all entries reviewed by a panel of independent experts.

“To be selected speaks to the quality of the clinical and pre-clinical evidence demonstrating the superior performance and durability of DurAVR™ and the genuine interest in its potential to significantly improve outcomes for patients.”  

Transcatheter therapies

PCR London Valves is the world’s largest educational meeting focused on transcatheter therapies for valvular heart disease.

It attracts interventional cardiologists, cardiac surgeons, heart teams and industry partners committed to the field of structural heart solutions.

Presentations for 'Best Innovation' are selected in a competitive, peer-reviewed process with Anteris’ DurAVR™ the only aortic valve being featured in the Best Innovations section.

Results presentation

Professor Bart Meuris MD, PhD, chief of cardiovascular surgery at the University Hospitals, Leuven, Belgium and principal investigator of Anteris Technologies’ first-in-human study will present on the company’s behalf.

Dr Meuris will provide an overview of the DurAVR™ heart valve and results generated to date in the first-in-human study.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

Quick facts: Anteris Technologies Ltd

Price: 5.03 AUD

ASX:AVR
Market: ASX
Market Cap: $31.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Anteris Technologies CEO hails 'very good results' from DurAVR™ human study

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson caught up with Proactive's Andrew Scott soon after reporting that early results from its first-in-human study of its proprietary DurAVR™ aortic valve found that patient outcomes exceeded the results of what is normally expected following a...

on 19/10/20

2 min read